yourstate.us
21 CFR 60.26

§ 60.26 Final action on regulatory review period determinations.

United States · 21 CFR — Food and Drugs · Status: effective

Get this as JSONEmbed this
Cite this
Citation
21 CFR 60.26, § 60.26 Final action on regulatory review period determinations, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/83555
Permanent ID
ys:prov:83555@1
SHA-256
85998a857764052aa5dc93cc634b7e47ccb0b88f0b69cc4aad63de5b6656e4df

The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.

Full text

(a) FDA will consider a regulatory review period determination to be final upon expiration of the 180-day period for filing a due diligence petition under § 60.30 unless FDA receives: (1) New information from PTO records, FDA records, or FDA centers that affects the regulatory review period determination; (2) A request under § 60.24 for revision of the regulatory review period determination; (3) A due diligence petition filed under § 60.30; or (4) A request for a hearing filed under § 60.40. (b) FDA will notify PTO that the regulatory review period determination is final upon: (1) The expiration of the 180-day period for filing a due diligence petition; or (2) If FDA has received a request for a revision, a due diligence petition, or a request for a hearing, upon resolution of the request for a revision, the petition, or the hearing, whichever is later. FDA will send a copy of the notification to the applicant and file a copy of the notification in the docket established for the application in FDA's Dockets Management Staff (HFA-305), 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

Legislative history

This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.